Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FQWD2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $29,284
Award facts
- Contract value 100% obligated
- $29,284.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $29,284.08 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. This delivery order was issued without a set-aside designation on November 24, 2025, with an ultimate completion date of November 25, 2025. The award represents one of multiple delivery orders issued to DMS Pharmaceutical Group under the agency's broader pharmaceutical supply chain operations supporting Department of Defense medical facilities.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. That parent contract, awarded on November 13, 2025, carries a $499,999,999 ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a regional prime vendor contractor within the $30.3 billion PPV-G GEN V acquisition strategy. The PPV-G GEN V program authorizes DLA to issue delivery orders for comprehensive pharmaceutical products and medical consumables to support military healthcare operations globally, and DMS Pharmaceutical Group's established performance demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FQWD2?
SPE2DR26FQWD2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 24, 2025.
How much is contract SPE2DR26FQWD2 worth?
The government has obligated $29,284 on SPE2DR26FQWD2.
Is contract SPE2DR26FQWD2 an order under another contract?
Yes. SPE2DR26FQWD2 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWD2 competed?
The extent of competition for SPE2DR26FQWD2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award